These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479 [TBL] [Abstract][Full Text] [Related]
35. Features associated with the development of hallucinations in Parkinson's disease. Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542 [TBL] [Abstract][Full Text] [Related]
36. Levodopa: long-term impact on Parkinson's disease. Br Med J (Clin Res Ed); 1981 Feb; 282(6262):417-8. PubMed ID: 6780051 [No Abstract] [Full Text] [Related]
37. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Goetz CG; Wuu J; Curgian L; Leurgans S Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144 [TBL] [Abstract][Full Text] [Related]
38. Pathophysiology of motor fluctuations in Parkinson's disease. Widnell K Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108 [TBL] [Abstract][Full Text] [Related]
39. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446 [No Abstract] [Full Text] [Related]
40. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Zoldan J; Friedberg G; Weizman A; Melamed E Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]